3-Arylisoquinolines as novel topoisomerase I inhibitors

Area of Science:

• Biochemistry and Molecular Biology
• Medicinal Chemistry
• Oncology

Background:

• Topoisomerase I (topo I) is a vital enzyme and a key target for cancer therapy.
• Camptothecin derivatives are potent topo I inhibitors but have limitations like toxicity and resistance.
• Development of non-camptothecin topo I inhibitors is crucial for improved cancer treatment.

Purpose of the Study:

• To review the development of novel non-camptothecin topo I inhibitors.
• To highlight the 3-arylisoquinoline scaffold as a common structural motif in these inhibitors.
• To explore new classes of compounds targeting topo I.

Main Methods:

• Literature review of studies on non-camptothecin topo I inhibitors.
• Analysis of the 3-arylisoquinoline scaffold in various inhibitor classes.
• Description of novel indeno[1,2-c]isoquinolines, isoindolo[2,1-b]isoquinolines, 12-oxobenzo[c]phenanthridines, and benz[b]oxepines.

Main Results:

• The 3-arylisoquinoline scaffold is a common feature in effective non-camptothecin topo I inhibitors.
• Novel indeno[1,2-c]isoquinolines, isoindolo[2,1-b]isoquinolines, 12-oxobenzo[c]phenanthridines, and benz[b]oxepines have been developed.
• These compounds represent promising alternatives to camptothecin-based drugs.

Conclusions:

• Non-camptothecin topo I inhibitors with a 3-arylisoquinoline nucleus offer a promising avenue for cancer drug development.
• Further research into these novel scaffolds may lead to more effective and safer anticancer agents.
• Targeting topoisomerase I remains a validated strategy in oncology.